Pfizer (PFE) Q4 FY25 earnings call

Pfizer delivered strong Q4 FY25 results, exceeding financial commitments and demonstrating resilience despite a soft COVID season. The company is strategically investing in its pipeline and recent acquisitions, particularly in obesity and oncology, to drive growth towards the end of the decade, while reaffirming its FY26 guidance and focusing on productivity through AI.